ESTRO 35 2016 ______________________________________________________________________________________________________ predicted for clinical and biochemical failures. MVA indicates that RBP is an independent risk factor for biochemical failure (p= 0.003, HR= 0.6) while it is the strongest risk factor for clinical failures and PCa deaths (p<0.0001, HR<0.5, regression coefficient b<-0.5). No statistical significant difference in rectal volume between RBP (mean volume 62.4±24.5 cc) and NRPB (mean volume 63.4±27 cc) was observed (chi square p value equal to 0.52)
Purpose or Objective: The aim of the study is to prospectively evaluate urinary symptoms using the International Prostate Symptom Score (IPSS) in patients with localized prostate cancer (CaP) treated with radical (RRT) or postprostatectomy (PRT) radiotherapy delivered with conventional (CONV) or moderately hypofractionated (HYPO) fractionation.
Material and Methods:
We considered patients enrolled in the two multicentric prospective observational studies DUE01 (RRT, CONV and HYPO) and IHU WPRT TOX (RRT and PRT, including irradiation of the pelvic lymphnodal area, CONV and HYPO). The IPSS questionnaire, evaluating 7 symptoms (IPSS1-IPSS7) and a quality of life (IPSS8), is filled in before and at the end of RT, then 3 and 6 after treatment end and every 6 months thereafter up to 5 years after the end of treatment. In this preliminary analysis only data relative to first year will be analyzed. Longitudinal trends were assessed by analysis of variance (anova).
Results:
The analysis pertains to 146 RRT CONV pts, 104 RRT HYPO pts, 74 PRT CONV pts and 94 PRT HYPO. The median age in the 2 studies was 71 (RRT) and 66 (PRT) years (p = 0.0001). Overall, urinary function was always better in the RRT CONV cohort. Statistically significant differences among the 4 groups have emerged with respect to urinary frequency, urgency, effort, nocturia. When comparing RRT vs PRT, frequency (p = 0.007) and stress (p = 0.01) were significantly more present in PRT, while only a borderline difference in terms of urgency (p = 0.07) was evident. The last item of IPSS shows a significant difference of quality of life between groups, especially at 12 month where RRT cohort, especially CONV, shows a better score than PRT patients. Figure 1 shows the comparison of each group for all IPSS items (incomplete emptyng, urinary frequency, intermittence, urgency, urinary stream, obstruction, nocturia, QoL), evaluating the mean response in the first five time of compilation (Rt start, RT end, 3m, 6m, 12m).
Conclusion:
These preliminary results seem to suggest that RRT would result in less deterioration of urinary symptoms over time than PRT, especially RRT with conventional fractionation. Further analyses are ongoing in order to study the effect of baseline urinary situation, age, doses to the bladder and the impact of each urinary symptoms on quality of life.
PO-0754 Whole body Integral dose is associated with radiotherapy related fatigue in prostate cancer N. Joseph
Purpose or Objective: Although intensity modulated radiotherapy (IMRT) permits the delivery of a highly conformal dose to target volumes while sparing dose to identified organs at risk, it results in a higher whole body integral dose due to irradiation of a larger volume of tissue at lower doses. A randomized clinical trial in head and neck cancer comparing IMRT with 3-D conformal radiotherapy, demonstrated higher acute fatigue in the IMRT cohort, raising the possibility of an association with higher integral dose. We hypothesized that a higher integral whole body dose is associated with worsening fatigue and an adverse functional outcome in patients with localized prostate cancer treated with intensity modulated external beam radiotherapy.
Material and Methods: 26 patients with localized adenocarcinoma of prostate treated with intensity modulated external beam radiotherapy were included in this analysis. The integral dose was calculated as the product of mean body dose and body volume and the study cohort was dichotomized using the median integral dose as the cut-off value. The fatigue, physical functioning and role functioning domains of the EORTC QLQ-C30 questionnaire prior to radiotherapy and upon completion of radiotherapy were assessed. The outcome measure was defined as worsening in any of these three domains.
Results: The median integral dose was 119.7 litre-Gy (range 90.5 -168.1). In the whole population 17/26 (65%) had worsening of fatigue, physical or role functioning. A significantly higher proportion of patients with an integral dose above median had worsening fatigue, physical and role functioning compared with patients with an integral dose below median. (6/13 versus 11/13; z test for proportions p=0.04).
Conclusion:
To our knowledge, this is the first study linking acute worsening of fatigue and functional outcome with whole body integral dose. Further validation in a larger cohort and in different tumour sites is necessary and the relationship between integral dose and toxicity merits further investigation.
PO-0755
Intestinal toxicity from WPRT delivered with IMRT is negligible. A multicentric observational trial. C. Sini 
